Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB | P05771 | 12/20 | 1.00 |
| ▸ | PRKCA | P17252 | 12/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 7/20 | 0.59 |
| ▸ | PRKCH | P24723 | 6/20 | 0.59 |
| ▸ | PRKCE | Q02156 | 6/20 | 0.59 |
| ▸ | PRKCQ | Q04759 | 6/20 | 0.59 |
| ▸ | CAMK2D | Q13557 | 4/20 | 0.59 |
| ▸ | PRKACA | P17612 | 3/20 | 0.59 |
| ▸ | PRKACG | P22612 | 3/20 | 0.59 |
| ▸ | PRKACB | P22694 | 3/20 | 0.59 |
| ▸ | CDK4 | P11802 | 3/20 | 0.59 |
| ▸ | CCND1 | P24385 | 3/20 | 0.59 |
| ▸ | CDK2 | P24941 | 3/20 | 0.59 |
| ▸ | ABL1 | P00519 | 2/20 | 0.59 |
| ▸ | CCNE2 | O96020 | 2/20 | 0.59 |
| ▸ | CCNE1 | P24864 | 2/20 | 0.59 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.59 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.59 |
| ▸ | PRKCG | P05129 | 1/20 | 0.59 |
| ▸ | CDK1 | P06493 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3587074 | 0.91 | PRKCB (0.83) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3540954 | 0.86 | PRKCB (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3543360 | 0.85 | PRKCB (0.73) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3537230 | 0.77 | PRKCA (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| Ro-316233 SCHEMBL29373011 | 0.77 | PRKCB (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| Ro-316233 SCHEMBL624896 | 0.77 | PRKCB (1.00) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL6982683 | 0.75 | PRKCB (0.67) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3582396 | 0.75 | PRKCB (0.60) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL3540477 | 0.74 | PRKCB (0.76) | PRKCBPRKCAPRKCDPRKCHPRKCE | |
| SCHEMBL6030821 | 0.73 | PRKCB (0.68) | PRKCBPRKCAPRKCDPRKCHPRKCE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1745037-B1 | Indolylmaleimide derivatives as inhibitors for the treatment of graft rejection or autoimmune diseases | NOVARTIS AG (CH) | 2013-01-02 | — | — | EP | claimed |
| US-7648989-B2 | Indolylmaleimide derivatives as PKC inhibitors | NOVARTIS AG (CH) | 2010-01-19 | — | — | US | claimed |
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | NOVARTIS AG (CH) | 2008-10-02 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080242675-A1 | Indolylmaleimide Derivatives as Pkc Inhibitors | PRKCE, PRKCH, PRKCI | PRKCB 5/4885PRKCA 4/4885PRKCD 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.